Q-omics provides the consensus-scored TUT1 profile across patient tissues and cancer cell-line models. TUT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TUT1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TUT1 RNA expression shows 19,160 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where TUT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUT1 survival associations across molecular data types. TUT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUT1 RNA expression–survival associations across cancer types. High TUT1 expression shows unfavorable associations in ACC, COAD, KIRC and BLCA, but favorable associations in UCS and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TUT1 RNA expression.
This table summarizes TUT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TUT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUT1 shows higher tumor expression in KIRC, COAD, HNSC, BLCA, STAD and LIHC. The KIRC box plot shows higher TUT1 RNA expression in tumor versus normal tissue (log2 FC = +0.338, t-test p < 0.001).
This table shows molecular features associated with TUT1 in patient tissues and cancer cell lines. In patient samples, TUT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
